Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296426 · ClinicalTrials.gov registry record · NA
Implementation and Evaluation of a Medical Reconciliation Protocol at Brigham and Women's Hospital
A NA study of Medication Reconciliation, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 322
- Enrollment target
- 1
- Study location
NCT00296426: Completed NA study of Medication Reconciliation, sponsored by Brigham and Women's Hospital.
NCT00296426 is a NA study of Medication Reconciliation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 322 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00296426, a NA study of Medication Reconciliation, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 322 participants
- Enrollment target
- 1
- Study location
Study Summary
An incomplete understanding of patients' preadmission medications and failure to reconcile these with medications ordered in the hospital and at discharge are major, previously unappreciated, causes of adverse drug events (ADEs). The Joint Commission for Accreditation of Healthcare Organizations has now mandated a process for reconciling all medications at hospital admission and discharge. The best ways to implement medication reconciliation and the impact on patient outcomes are unknown. We, the researchers at at Brigham and Women's Hospital, will design and implement a medication reconciliation process with two major components: 1) information technology to integrate medication reconciliation into the current workflow at Brigham and Women's Hospital (BWH); and 2) process re-design involving physicians, nurses, and pharmacists to ensure that reconciliation takes place. We will then conduct a randomized controlled trial on the General Medical Service of BWH to evaluate the effects of this new process on reducing medication reconciliation errors with the potential to cause patient harm (potential ADEs).
Conditions Studied
Interventions
- PROCEDURE New technology - PAML
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 322 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-08 |
| Phase | NA |
What the finished NCT00296426 record still lists
NCT00296426 is an interventional study that assigns participants to a tested intervention. The registered 322 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Medication Reconciliation appearing as the primary indexed condition, and to 1 intervention - of which New technology - PAML is the first listed.
NCT00296426 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00296426 about?
NCT00296426 is a clinical study titled "Implementation and Evaluation of a Medical Reconciliation Protocol at Brigham and Women's Hospital". An incomplete understanding of patients' preadmission medications and failure to reconcile these with medications ordered in the hospital and at discharge are major, previously unappreciated, causes of adverse drug events (ADEs). The Joint Commission for Accreditation of Healthcare Organizations has...
What is the current status of trial NCT00296426?
This trial is currently completed. It is a NA study. The enrollment target is 322 participants. The study started on 2006-05. Estimated completion is 2010-08.
What conditions does trial NCT00296426 study?
This clinical trial studies the following conditions: Medication Reconciliation.
What interventions are being tested in trial NCT00296426?
The interventions under investigation include: New technology - PAML (PROCEDURE).
Who is sponsoring clinical trial NCT00296426?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00296426 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00296426's enrollment target sits among peer trials
322 315th of 2000 higher than 1,686 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia